News

US FDA Approval of Speedboat RS2

Approval comes ahead of schedule; Company to implement commercial plans

Read More

Creo Medical Announces Participation in SUMCASTEC Research Programme

Multidisciplinary Consortium Awarded €4 Million Grant Programme Focused on Isolation and Neutralization of Cancer Stem Cells

Read More

Admission to AIM and First Day of Dealings

Chepstow, South Wales, 9 December 2016 – Creo Medical Group plc (AIM: CREO) (“Creo” or the “Company”), a medical device company focused on the emerging field of surgical endoscopy, is pleased to announce the admission from 8:00 am today of its ordinary shares to trading on AIM, a market operated by the London Stock Exchange plc ("Admission") and the commencement of dealings in its Ordinary Shares under the TIDM "CREO" and with ISIN number GB00BZ1BLL44.

Read More

Placing and Proposed Admission to Trading on AIM

Chepstow, South Wales, 6 December 2016 – Creo Medical Group plc (AIM: CREO) (“Creo” or the “Company”), a medical device company focused on the emerging field of surgical endoscopy, is pleased to announce that it has today published an admission document (the “Admission Document”) in relation to the proposed admission of the entire issued share capital of the Company to trading on the AIM Market of the London Stock Exchange, which is expected to take place on 9 December 2016 (“Admission”).    

Read More